Cognitive effects of atypical antipsychotic drugs in first-episode drug-nave schizophrenic patients  

作　　者：Juan Wang Maorong Hu Xiaofeng Guo Renrong Wu Lehua Li Jingping Zhao 

机构地区：[1]Mental Health Institute of Second Xiangya Hospital,Central South University

出　　处：《Neural Regeneration Research》2013年第3期277-286,共10页中国神经再生研究（英文版）

基　　金：sponsored by the National Key Project of Scientific and Technical Supporting Programs Funded by the Ministry of Science & Technology of China,No.2007BAI17B04;the National Natural Science Foundation of China,No.30900485;the National R&D Special Fund for Health Professions,No.201002003

摘　　要：Cognitive impairment is a core feature of schizophrenia. The present randomized open study enrolled antipsychotic-naTve patients who were experiencing their first episode of schizophrenia. After baseline neurocognitive tests and clinical assessment, subjects were randomly assigned to olanzapine, risperidone and aripiprazole treatment groups. A battery of neurocognitive tests showed that risperidone produced cognitive benefits in all five cognitive domains, including verbal learning and memory, visual learning and memory, working memory, processing speed, and selective attention; olanzapine improved processing speed and selective attention; and aripiprazole improved visual learning and memory, and working memory. However, the three atypical antipsychotic drugs failed to reveal any significant differences in the composite cognitive scores at the study endpoint. In addition, the three drugs all significantly improved clinical measures without significant differences between the drugs after 6 months. These results suggest that the atypical antipsychotics, olanzapine, risperidone and aripiprazole may improve specific cognitive domains with similar global clinical efficacy. In clinical practice, it may be feasible to choose corresponding atypical antipsychotics according to impaired cognitive domains.Cognitive impairment is a core feature of schizophrenia. The present randomized open study enrolled antipsychotic-naTve patients who were experiencing their first episode of schizophrenia. After baseline neurocognitive tests and clinical assessment, subjects were randomly assigned to olanzapine, risperidone and aripiprazole treatment groups. A battery of neurocognitive tests showed that risperidone produced cognitive benefits in all five cognitive domains, including verbal learning and memory, visual learning and memory, working memory, processing speed, and selective attention; olanzapine improved processing speed and selective attention; and aripiprazole improved visual learning and memory, and working memory. However, the three atypical antipsychotic drugs failed to reveal any significant differences in the composite cognitive scores at the study endpoint. In addition, the three drugs all significantly improved clinical measures without significant differences between the drugs after 6 months. These results suggest that the atypical antipsychotics, olanzapine, risperidone and aripiprazole may improve specific cognitive domains with similar global clinical efficacy. In clinical practice, it may be feasible to choose corresponding atypical antipsychotics according to impaired cognitive domains.

关 键 词：neural regeneration clinical practice OLANZAPINE RISPERIDONE ARIPIPRAZOLE schizophrenia cognition memory grant-supported paper NEUROREGENERATION 

分 类 号：R749.3[医药卫生—神经病学与精神病学]